These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 31183384)

  • 21. Once-weekly dulaglutide versus insulin glargine in the early control of fasting serum glucose and HbA1c.
    Romera I; Conget I; Vazquez LA; Gentilella R; Lebrec J; Jódar E; Reviriego J
    J Diabetes Complications; 2020 Jul; 34(7):107575. PubMed ID: 32220551
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5).
    Nauck M; Weinstock RS; Umpierrez GE; Guerci B; Skrivanek Z; Milicevic Z
    Diabetes Care; 2014 Aug; 37(8):2149-58. PubMed ID: 24742660
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3).
    Umpierrez G; Tofé Povedano S; Pérez Manghi F; Shurzinske L; Pechtner V
    Diabetes Care; 2014 Aug; 37(8):2168-76. PubMed ID: 24842985
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Patient-reported Outcomes in Patients with Type 2 Diabetes Treated with Dulaglutide Added to Titrated Insulin Glargine (AWARD-9).
    Yu M; Brunt KV; Milicevic Z; Varnado O; Boye KS
    Clin Ther; 2017 Nov; 39(11):2284-2295. PubMed ID: 29110972
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of the impact of once weekly dulaglutide on patient-reported outcomes in Japanese patients with type 2 diabetes: comparisons with liraglutide, insulin glargine, and placebo in two randomized studies.
    Suzuki S; Oura T; Takeuchi M; Boye KS
    Health Qual Life Outcomes; 2017 Jun; 15(1):123. PubMed ID: 28606095
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of once weekly dulaglutide by baseline beta-cell function in people with type 2 diabetes in the AWARD programme.
    Mathieu C; Del Prato S; Botros FT; Thieu VT; Pavo I; Jia N; Haupt A; Karanikas CA; García-Pérez LE
    Diabetes Obes Metab; 2018 Aug; 20(8):2023-2028. PubMed ID: 29603872
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment patterns in patients with type 2 diabetes mellitus treated with glucagon-like peptide-1 receptor agonists: Higher adherence and persistence with dulaglutide compared with once-weekly exenatide and liraglutide.
    Alatorre C; Fernández Landó L; Yu M; Brown K; Montejano L; Juneau P; Mody R; Swindle R
    Diabetes Obes Metab; 2017 Jul; 19(7):953-961. PubMed ID: 28181725
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Achieving the composite endpoint of glycated haemoglobin <7.0%, no weight gain and no hypoglycaemia in the once-weekly dulaglutide AWARD programme.
    Dungan KM; Raz I; Skrivanek Z; Sealls W; Fahrbach JL
    Diabetes Obes Metab; 2016 Jan; 18(1):49-55. PubMed ID: 26362460
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Early fasting glucose measurements can predict later glycaemic response to once weekly dulaglutide.
    Grunberger G; Forst T; Fernández Landó L; Pechtner V; Shaginian R; Jia N; Gough S
    Diabet Med; 2016 Mar; 33(3):391-4. PubMed ID: 26179454
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Monotherapy with the once weekly GLP-1 receptor agonist dulaglutide for 12 weeks in Japanese patients with type 2 diabetes: dose-dependent effects on glycaemic control in a randomised, double-blind, placebo-controlled study.
    Terauchi Y; Satoi Y; Takeuchi M; Imaoka T
    Endocr J; 2014; 61(10):949-59. PubMed ID: 25029955
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Subgroup analysis of phase 3 studies of dulaglutide in Japanese patients with type 2 diabetes.
    Onishi Y; Oura T; Nishiyama H; Ohyama S; Takeuchi M; Iwamoto N
    Endocr J; 2016; 63(3):263-73. PubMed ID: 26698689
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of dulaglutide added onto pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD-1).
    Wysham C; Blevins T; Arakaki R; Colon G; Garcia P; Atisso C; Kuhstoss D; Lakshmanan M
    Diabetes Care; 2014 Aug; 37(8):2159-67. PubMed ID: 24879836
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Real-world effectiveness, adherence and persistence among patients with type 2 diabetes mellitus initiating dulaglutide treatment.
    Mody R; Grabner M; Yu M; Turner R; Kwan AYM; York W; Fernández Landó L
    Curr Med Res Opin; 2018 Jun; 34(6):995-1003. PubMed ID: 29271258
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative effectiveness of once-weekly glucagon-like peptide-1 receptor agonists with regard to 6-month glycaemic control and weight outcomes in patients with type 2 diabetes.
    Unni S; Wittbrodt E; Ma J; Schauerhamer M; Hurd J; Ruiz-Negrón N; McAdam-Marx C
    Diabetes Obes Metab; 2018 Feb; 20(2):468-473. PubMed ID: 28862808
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dulaglutide 1.5 mg as an add-on option for patients uncontrolled on insulin: Subgroup analysis by age, duration of diabetes and baseline glycated haemoglobin concentration.
    Pantalone KM; Patel H; Yu M; Fernández Landó L
    Diabetes Obes Metab; 2018 Jun; 20(6):1461-1469. PubMed ID: 29430801
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adherence, persistence, glycaemic control and costs among patients with type 2 diabetes initiating dulaglutide compared with liraglutide or exenatide once weekly at 12-month follow-up in a real-world setting in the United States.
    Mody R; Huang Q; Yu M; Zhao R; Patel H; Grabner M; Landó LF
    Diabetes Obes Metab; 2019 Apr; 21(4):920-929. PubMed ID: 30520248
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Baseline factors associated with glycaemic response to treatment with once-weekly dulaglutide in patients with type 2 diabetes.
    Wysham C; Guerci B; D'Alessio D; Jia N; Botros FT
    Diabetes Obes Metab; 2016 Nov; 18(11):1138-1142. PubMed ID: 27265893
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Once-Weekly Dulaglutide for the Treatment of Youths with Type 2 Diabetes.
    Arslanian SA; Hannon T; Zeitler P; Chao LC; Boucher-Berry C; Barrientos-Pérez M; Bismuth E; Dib S; Cho JI; Cox D;
    N Engl J Med; 2022 Aug; 387(5):433-443. PubMed ID: 35658022
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and safety of once-weekly glucagon-like peptide-1 receptor agonists compared with exenatide and liraglutide in type 2 diabetes: a systemic review of randomised controlled trials.
    Xue X; Ren Z; Zhang A; Yang Q; Zhang W; Liu F
    Int J Clin Pract; 2016 Aug; 70(8):649-56. PubMed ID: 27456750
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The efficacy and safety of adding either vildagliptin or glimepiride to ongoing metformin therapy in patients with type 2 diabetes mellitus.
    Kim G; Oh S; Jin SM; Hur KY; Kim JH; Lee MK
    Expert Opin Pharmacother; 2017 Aug; 18(12):1179-1186. PubMed ID: 28714741
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.